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To the Editor: Cerebral venous thrombosis (CVT) indicates occlusion of the main sinus/sinuses or cortical veins, resulting in vascular congestion and neurological lesions. [1] Juveniles with Down syndrome (DS) are more likely to develop thrombosis. [2] However, the association between thrombosis and DS has not been reported widely.
An 18-year-old man with a history of DS was admitted due to severe headache, nausea, and vomiting. He soon lost consciousness and had exhibited gastric bleeding within the past 10 days. He had no history of other diseases and no family history of thrombotic disorders or cerebrovascular diseases. On physical examination, the patient was in a light coma, with neck resistance, and other physical examinations were precluded by the patient's condition. Initial therapeutic approaches included low-molecular-weightheparin-calcium (fraxiparine) by subcutaneous injection, protection of gastric mucosa, reduction of intracranial pressure, and fluid infusion. After 4 days of therapy, the patient's lower left extremity was tumescent, and bedside color Doppler ultrasound demonstrated that he had widespread thrombosis in the lower extremity. No improvements in MRI or clinical condition were observed. In light of poor anticoagulant efficacy and the specificity of the patient, we considered that his CVT might be caused by a potential autoimmune condition. He was therefore administrated immunosuppressive therapy with antimicrobial protection. Following a 3-day treatment with methylprednisolone, 80 mg/d, his symptoms were slightly improved. Additional laboratory tests showed D-dimer 0.78 mg/L, ESR 42 mm/h, and CRP 18 mg/L. We then reduced the methylprednisolone dose to 40 mg/day and continued fraxiparine for 3 days. Later, the patient received prednisone 30 mg alone, along with 110 mg of an oral anticoagulant (dabigatran). The treatment was successful as subsequent MRI revealed abnormal signals and lesions of the bithalamus, but the left periventricular structure was significantly reduced compared to the previous MRI [ Figure 1e -1g]. Ultrasound examination confirmed that the lower limb thrombosis was clearly alleviated. After 6-month follow-up, the patient continued oral anticoagulation and had no further episodes of thrombosis or new symptoms.
Genetic factors or autoimmune factors might contribute to high incidence of CVT in patients with DS. Wilcock et al. [3] demonstrated that DS could be triggered by abnormal proteins, including superoxide dismutase 1, collagen type VI, and cystathionine β-synthase, which are encoded on chromosome 21. These abnormal proteins might be involved in pro-inflammatory processes and complement activation, leading to potential thrombogenesis. [4] Medina et al. [5] reported a patient with DS who presented with right-hand ischemia followed by arterial and venous thrombosis of the right thoracic extremity and was finally diagnosed with catastrophic antiphospholipid syndrome. In our case, we applied glucocorticoids to inhibit inflammatory reactions and achieved good results.
In summary, this is a rare case report on the auxiliary examination, diagnosis, and successful therapeutic treatment of CVT in a patient with DS. Our case suggests that combined therapy of anticoagulants Progressive Venous Thrombosis in an 18-Year-Old Man with Down Syndrome and glucocorticoids might be feasible for the treatment of progressive venous thrombosis in DS patients.
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